Additional data presented investigates
real-world outcomes for patients with metastatic non-small cell
lung cancer
Ontada®, a McKesson business dedicated to leveraging oncology
real-world evidence (RWE), clinical education, and provider
technology to transform the fight against cancer, presented new
data at the American Society of Clinical Oncology (ASCO) Annual
Meeting which showed that 74 percent of patients with
triple-negative breast cancer (TNBC) treated in a U.S community
oncology network received genetic testing. However, significantly
lower testing rates were observed for patients who were Black, had
lower socioeconomic status, and resided in Southern or Midwestern
geographic regions.
In terms of treatment, researchers, in an additional study, did
not observe inequities in the use of neoadjuvant chemotherapy (NC)
based on social determinants of health (SDOH) analyzed, such as
race, ethnicity, and Area Deprivation Index (ADI), a validated
measure of socioeconomic status. Poorer outcomes observed in Black
patients with TNBC may not be a result of underutilization of
NC.
This research is part of Ontada’s HOPE Studies (Health Outcomes
Powered by Evidence), a program enabling providers to investigate
unanswered questions through retrospective, non-interventional
studies.
“This new data provides insights on the crossroads of SDOH and
TNBC, an aggressive form of one of the most common cancers, which
disproportionately affects different patient populations with poor
outcomes,” said study co-author Nicholas Robert, MD, chief medical
officer, Ontada. “Studies addressing SDOH, such as these, have
clinical real-world applicability to help identify potential
factors that may impact care and outcomes for affected communities.
To address barriers, further research should be performed to
understand reasons why testing was not done.”
Additional Ontada-affiliated studies were also presented at the
Annual Meeting, one of which examined the availability and
consistency of treatment response rate endpoints in patients with
metastatic non-small cell lung cancer (mNSCLC) treated with
chemotherapy across real-world datasets to understand how the
utility of the data can be improved. Leveraging real-world data and
evidence is significant and can accelerate development and access
to needed treatments. In this study, seven organizations worked
together to evaluate how real-world data (RWD) can be used to
assess real-world response in patients with mNSCLC. While
variability in the availability of data components to assess
response was observed, the demonstrated feasibility of response
endpoints based on clinical assessment suggests further exploration
may inform drug effectiveness evaluation with RWD.
“Real-world response is an important outcome in clinical
oncology studies and is used to evaluate the effectiveness of
treatments in the real world. However, there is no recognized
standard for how this is assessed,” said study co-author Janet
Espirito, PharmD, senior medical director, Ontada. “The primary
goal of this study was to evaluate the availability and consistency
of information across data sources. If several organizations used
the same measures, would we get the same outcomes? We learned that
there are consistencies, but now as industry leaders, we must
continue to work together to develop best practices.”
The full schedule of Ontada-affiliated studies being featured at
ASCO, including authorship information, can be found here.
About the Studies
The impact of social determinants of health (SDOH) on use of
germline genetic testing for triple-negative breast cancer (TNBC)
in the community oncology setting (ASCO Poster)
This was a retrospective observational cross-sectional study
examining patient profiles, demographics, SDOH indicators, and
germline genetic testing data. Patients in The US Oncology Network
diagnosed with any stage TNBC between 3/31/2017 and 9/30/2021 aged
60 years or younger were identified. Data from the iKnowMed
electronic health record (EHR) was used for patient identification,
baseline characteristics, and social determinants, including area
deprivation index (ADI), a validated measure of socioeconomic
status (SES) based on address. Mean ADI percentile scores using
national and state level benchmarks were calculated as well as
stratifications above and below the 80th percentile (where higher
scores > 80 are markers of low SES). Evidence of germline
genetic testing (yes/no) was compiled from iKM, network genetic
databases, and confirmatory chart audits. Only The US Oncology
Network sites participating in confirmatory audits were included in
this analysis.
Social determinants of health and utilization of neoadjuvant
chemotherapy in patients with triple negative breast cancer (TNBC)
in the community oncology setting (ASCO Poster)
This retrospective observational cross-sectional study examined
patient profiles, treatment patterns, and SDOH indicators among
patients newly diagnosed with early-stage breast cancer in The US
Oncology Network. Using iKnowMed EHR data, patients diagnosed with
TNBC between 03/31/2017 and 09/30/2021 with stages II-IIIB disease
or tumor size ≥2cm (T2 or higher) were included. The initial TNBC
diagnosis date was used as the index date for each patient and
records were assessed from 6 months pre- to 6 months post-diagnosis
for NC initiation, baseline characteristics, and social
determinants, including Area Deprivation Index (ADI), a validated
measure of socioeconomic status.
Real-world response endpoints in patients with mNSCLC treated
with chemotherapy across real-world datasets (ASCO Poster)
This study included seven EHR data partners who identified and
analyzed a cohort of 1,380 patients (pts) with metastatic non-small
cell lung cancer (mNSCLC) treated with first-line platinum doublet
chemotherapy, following a common protocol and statistical analysis
plan. The availability and frequency of data components to assess
response including raw images, radiology imaging reports, and
clinician response assessments from provider notes were assessed.
Response endpoints measured included real-world response rate
(rwRR), real-world-duration of response (rwDOR), and the
association of real-world response with real-world-overall survival
(rwOS), real-world-time to treatment discontinuation (rwTTD), and
real-world-time to next treatment (rwTTNT).
About Ontada®
Ontada is an oncology technology and insights business dedicated
to transforming the fight against cancer. Part of McKesson
Corporation, Ontada was founded on the core belief that precise
insights – delivered exactly at the point of need – can save more
patients’ lives. We connect the full patient journey by combining
technologies used by The US Oncology Network and other community
oncology providers with real-world data and research relied on by
all top 15 global life sciences companies. Our work helps
accelerate innovation and power the future of cancer care. For more
information, visit ontada.com.
About McKesson Oncology and Specialty Solutions
It’s an unprecedented time for patients living with cancer as
life sciences companies race to create new, cutting-edge therapies.
With cancer care becoming more targeted, providers, life sciences
companies, and payers face a multitude of challenges and complexity
in the development of new treatments and making them accessible to
patients in need. At McKesson, our unmatched portfolio of oncology
businesses and partners provide research, insights, technologies,
and services that are helping to address these hurdles and improve
cancer and specialty care.
- McKesson is fueling discovery by helping patients participate
in cutting-edge clinical trials closer to home through the joint
venture between US Oncology Research and Sarah Cannon Research
Institute
- The US Oncology Network and McKesson Provider Solutions are
advancing specialty care and high-quality cancer care in the
communities where patients live by supporting the practices of
thousands of independent, community-based providers.
- Ontada®, a McKesson business dedicated to oncology, generates
real-world data (RWD) and real-world evidence (RWE) and provides
clinical education and provider technology to inform and improve
cancer care.
- As one of the largest distributors of oncology and specialty
medicines, we are ensuring medicines make their way to the those
who are counting on them.
- And through CoverMyMeds, Biologics by McKesson, and GPO
services, our work continues to help patients access, afford, and
adhere to their medicines.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230604005023/en/
Claire Crye, Public Relations, 281-825-9927,
claire.crye@mckesson.com